ANAB - ANAPTYSBIO, INC

QQQ $ 622.49 $ 0.90 (0.15 %)

DIA $ 479.63 $ 5.34 (1.13 %)

SPY $ 683.37 $ 2.90 (0.43 %)

TLT $ 89.91 $ 0.01 (0.01 %)

GLD $ 380.58 $ -0.09 (-0.02 %)

Previous Close

$ 33.56

Open

$ 33.03

Bid

$ 31.01 x 100

Ask

$ 38.63 x 70

Day's Range

$ 32.20 - $ 34.62

52 Week Range

$ 12.21 - $ 40.96

Volume

733,619

Average Volume

Market Cap

929.23M

Beta (5Y Monthly)

$ 0.64

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-04-2025	09-30-2025	10-Q
2	08-06-2025	06-30-2025	10-Q
3	05-05-2025	03-31-2025	10-Q
4	02-27-2025	01-01-1970	10-K
5	11-05-2024	09-30-2024	10-Q
6	08-05-2024	06-30-2024	10-Q
7	05-09-2024	03-31-2024	10-Q
8	03-11-2024	12-31-2023	10-K
9	11-02-2023	09-30-2023	10-Q
10	08-07-2023	06-30-2023	10-Q
11	05-11-2023	03-31-2023	10-Q
12	03-01-2023	12-31-2022	10-K
13	11-08-2022	09-30-2022	10-Q
14	08-08-2022	06-30-2022	10-Q
15	05-04-2022	03-31-2022	10-Q
16	03-07-2022	12-31-2021	10-K
17	11-04-2021	09-30-2021	10-Q
18	08-09-2021	06-30-2021	10-Q
19	05-04-2021	03-31-2021	10-Q
20	02-25-2021	12-31-2020	10-K
21	11-04-2020	09-30-2020	10-Q
22	08-10-2020	06-30-2020	10-Q
23	05-06-2020	03-31-2020	10-Q
24	03-02-2020	12-31-2019	10-K
25	11-08-2019	09-30-2019	10-Q
26	08-08-2019	06-30-2019	10-Q
27	05-07-2019	03-31-2019	10-Q
28	02-28-2019	12-31-2018	10-K
29	11-08-2018	09-30-2018	10-Q
30	08-07-2018	06-30-2018	10-Q
31	05-08-2018	03-31-2018	10-Q
32	03-05-2018	12-31-2017	10-K
33	11-07-2017	09-30-2017	10-Q
34	08-10-2017	06-30-2017	10-Q
35	05-12-2017	03-31-2017	10-Q
36	03-08-2017	12-31-2016	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Barclays Maintains Overweight on AnaptysBi...
11/11/2025 14:55:17

Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $83 to $70.

HC Wainwright & Co. Maintains Buy on Anapt...
11/11/2025 11:24:55

HC Wainwright & Co. analyst Emily Bodnar maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from ...

anaptysbio-to-save-10-million-after-discontinuing-ulcerative-colitis-study

AnaptysBio To Save $10 Million After Disco...
11/10/2025 17:30:44

AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and ...

Truist Securities Maintains Hold on Anapty...
11/10/2025 16:11:06

Truist Securities analyst John Lee maintains AnaptysBio (NASDAQ:ANAB) with a Hold and raises the price target from $20 to $36.

Trading Halt: Halt status updated at 9:45:...
11/10/2025 14:45:09

Anaptys Phase 2 Trial Of Rosnilimab Did No...
11/10/2025 14:03:07

Trading Halt: Halted at 8:55:00 a.m. ET - ...
11/10/2025 13:55:04

Guggenheim Maintains Buy on AnaptysBio, Ra...
11/05/2025 15:07:06

Guggenheim analyst Yatin Suneja maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $90 to $100.

Wells Fargo Maintains Overweight on Anapty...
11/05/2025 14:56:51

Wells Fargo analyst Derek Archila maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $51 ...

AnaptysBio Q3 EPS $0.52 Beats $(1.42) Esti...
11/04/2025 21:38:56

AnaptysBio (NASDAQ:ANAB) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $(1.42) by...

Stifel Maintains Buy on AnaptysBio, Raises...
10/29/2025 16:53:07

Stifel analyst Alex Thompson maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $55 to $80.

AnaptysBio Announces Late-Breaking Data Fr...
10/29/2025 13:19:06

New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, includi...

Wedbush Maintains Outperform on AnaptysBio...
10/15/2025 15:11:02

Wedbush analyst David Nierengarten maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $45...

AnaptysBio Says Complete Data From Phase 2...
10/13/2025 13:18:04

AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics...

Barclays Initiates Coverage On AnaptysBio ...
10/13/2025 12:02:06

Barclays analyst Etzer Darout initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Overweight rating and announces Price Ta...

anaptysbio-charts-path-to-split-into-two-public-companies-by-2026

AnaptysBio Charts Path To Split Into Two P...
09/30/2025 17:59:14

AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct...

12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 17:06:34

united-natural-foods-posts-upbeat-results-joins-anaptysbio-semtech-uipath-and-other-big-stocks-moving-higher-on-tuesday

United Natural Foods Posts Upbeat Results,...
09/30/2025 15:06:57

Wedbush Reiterates Outperform on AnaptysBi...
09/30/2025 12:57:13

Wedbush analyst Martin Fan reiterates AnaptysBio (NASDAQ:ANAB) with a Outperform and maintains $45 price target.

HC Wainwright & Co. Maintains Buy on Anapt...
09/30/2025 11:38:00

HC Wainwright & Co. analyst Emily Bodnar maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from ...